---
layout: post
title: New Drug Approvals 2011 - Pt. XVIII Ezogabine (PotigaTM)
date: '2011-06-21T15:20:00.004+01:00'
author: Ben
tags:
- 2011 New Drugs
- Small Molecule Drugs
modified_time: '2012-01-04T09:26:14.846Z'
thumbnail: http://2.bp.blogspot.com/-vYraVDaUB-4/Tf9tMtJCcFI/AAAAAAAAACk/KnK4Dq4EMT0/s72-c/800px-Retigabine.svg.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-3598000689331252234
blogger_orig_url: http://chembl.blogspot.com/2011/06/new-drug-approvals-2011-pt-xviii.html
---

<div center;"="" text-align:="">
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,1,0,0,0,0,0" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,1,0,0,0,0,0" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div style="text-align: center;">
<div style="text-align: center;">
<b>ATC code:</b>&nbsp;<a href="http://en.wikipedia.org/wiki/ATC_code_N03" title="ATC code N03">N03</a><span class="reflink plainlinks nourlexpansion"><a class="external text" href="http://www.whocc.no/atc_ddd_index/?code=N03AX21" rel="nofollow">AX21</a></span></div>
<div style="text-align: left;">
<br /></div>
</div>
</div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">On June 10th, FDA approved ezogabine (trade name </span><span class="Apple-style-span" style="font-family: inherit;"><a href="http://www.trademarkia.com/trademarks-search.aspx?tn=potiga">Potiga</a>, NDA 022345</span><span class="Apple-style-span" style="font-family: inherit;">) to treat seizures associated with </span><a href="http://en.wikipedia.org/wiki/Epilepsy"><span class="Apple-style-span" style="font-family: inherit;">epilepsy</span></a><span class="Apple-style-span" style="font-family: inherit;"> in adults. However, before being launched, Potiga waits categorised by the Drug Enforcement Agency (for &nbsp;review </span></span><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">under the&nbsp;</span><a href="http://en.wikipedia.org/wiki/Controlled_substances_act"><span class="Apple-style-span" style="font-family: inherit;">Controlled Substances Act</span></a></span><span class="Apple-style-span" style="font-family: inherit;">)&nbsp;before formal marketing can proceed.</span></div>
<div style="text-align: left;">
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span></div>
<div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Epilepsy is a chronic neurological disorder involving a variety of symptoms caused by abnormal electrical activity in the brain. Episodic bouts ('seizures') can potentially be controlled by medication - however, for around 1 in 3 patients, this can not achieved satisfactorily&nbsp;</span></span><span class="Apple-style-span" style="font-family: inherit;">with current medication.&nbsp;</span><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Ezogabine (ChEMBLID:</span><a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL41355"><span class="Apple-style-span" style="font-family: inherit;">41355</span></a><span class="Apple-style-span" style="font-family: inherit;">) represents a novel approach, being the first </span><a href="http://en.wikipedia.org/wiki/Anticonvulsant"><span class="Apple-style-span" style="font-family: inherit;">anticonvulsant</span></a><span class="Apple-style-span" style="font-family: inherit;"> to specifically target neuronal </span><a href="http://en.wikipedia.org/wiki/Potassium_channel"><span class="Apple-style-span" style="font-family: inherit;">potassium channels</span></a><span class="Apple-style-span" style="font-family: inherit;">.&nbsp;</span></span></div>
</div>
<div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><br />
</span> </span></div>
</div>
<div style="text-align: justify;">
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">The molecular targets of ezogabine are KCNQ/Kv7 potassium channels; by </span><a href="http://en.wikipedia.org/wiki/Potassium_channel_opener"><span class="Apple-style-span" style="font-family: inherit;">stabilizing their open conformation</span></a><span class="Apple-style-span" style="font-family: inherit;">, the drug reduces their excitability. It shares its mode of action with the structurally very similar non-opioid analgesic </span><a href="http://en.wikipedia.org/wiki/Flupirtine"><span class="Apple-style-span" style="font-family: inherit;">Flupiritine</span></a><span class="Apple-style-span" style="font-family: inherit;"> (ChEMBLID:</span><a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL255044"><span class="Apple-style-span" style="font-family: inherit;">255044</span></a><span class="Apple-style-span" style="font-family: inherit;">).</span></span><span class="Apple-style-span" style="font-family: inherit;"> There are numerous other anticonvulsant drugs approved, such as </span><a href="http://en.wikipedia.org/wiki/Carbamazepine"><span class="Apple-style-span" style="font-family: inherit;">Carbamazepine</span></a><span class="Apple-style-span" style="font-family: inherit;"> (ChEMBLID:</span><a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL108"><span class="Apple-style-span" style="font-family: inherit;">108</span></a><span class="Apple-style-span" style="font-family: inherit;">), or </span><a href="http://en.wikipedia.org/wiki/Lamictal"><span class="Apple-style-span" style="font-family: inherit;">Lamotrigine</span></a><span class="Apple-style-span" style="font-family: inherit;"> (ChEMBLID:</span><a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL741"><span class="Apple-style-span" style="font-family: inherit;">741</span></a><span class="Apple-style-span" style="font-family: inherit;">), two sodium channel blockers.&nbsp;</span></div>
</div>
<div style="text-align: justify;">
<div style="text-align: left;">
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span></div>
</div>
<div style="text-align: justify;">
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Its </span><a href="http://druginfo.nlm.nih.gov/drugportal/jsp/drugportal/DrugNameGenericStems.jsp"><span class="Apple-style-span" style="font-family: inherit;">name stem</span></a><span class="Apple-style-span" style="font-family: inherit;">, -gab-, designates it a </span><a href="http://en.wikipedia.org/wiki/Gamma-Aminobutyric_acid"><span class="Apple-style-span" style="font-family: inherit;">GABA</span></a><span class="Apple-style-span" style="font-family: inherit;"> mimetic (</span></span><span class="Apple-style-span" style="font-family: inherit;">Î³-Aminobutyric acid</span><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">, ChEMBL ID </span><a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL96"><span class="Apple-style-span" style="font-family: inherit;">96</span></a><span class="Apple-style-span" style="font-family: inherit;">, the predominant inhibitory neurotransmitter in the mammalian central nervous system). For a substance to be GABAergic, there is no need to directly compete with GABA, or to bind to the GABA receptor. However, </span><a href="http://www.sciencedirect.com/science/article/pii/S0014299903014262"><span class="Apple-style-span" style="font-family: inherit;">there is evidence</span></a><span class="Apple-style-span" style="font-family: inherit;"> that ezogabine directly interacts with the GABA</span><sub><span class="Apple-style-span" style="font-family: inherit;">A</span></sub><span class="Apple-style-span" style="font-family: inherit;"> receptor, acting as an allosteric agonist, synergetically increasing GABA binding, thereby excerting a sedative effect additionally to its primary target, KCNQ.</span></span></div>
<div style="text-align: left;">
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span></div>
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">The main molecular target of ezogabine are&nbsp;the human KCNQ2 and -3 potassium channels (UniProt </span><a href="http://www.uniprot.org/uniprot/O43526"><span class="Apple-style-span" style="font-family: inherit;">O43526</span></a><span class="Apple-style-span" style="font-family: inherit;"> and </span><a href="http://www.uniprot.org/uniprot/O43525"><span class="Apple-style-span" style="font-family: inherit;">O43525</span></a><span class="Apple-style-span" style="font-family: inherit;">, respectively) - </span><a href="https://www.ebi.ac.uk/chembldb/index.php/doc/inspect/CHEMBL1147528"><span class="Apple-style-span" style="font-family: inherit;">according to a patch clamp assay</span></a><span class="Apple-style-span" style="font-family: inherit;">, it has 1.3 uM affinity for the murine KCNQ2 ortholog (see also </span><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2587091/?tool=pubmed"><span class="Apple-style-span" style="font-family: inherit;">ref</span></a><span class="Apple-style-span" style="font-family: inherit;">).</span></span><span class="Apple-style-span" style="font-family: inherit;"> </span><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">There are no experimental structures available for members of the KCNQ protein family, although there are </span><a href="http://www.sciencemag.org/content/280/5360/56"><span class="Apple-style-span" style="font-family: inherit;">X-Ray structures</span></a><span class="Apple-style-span" style="font-family: inherit;"> for other potassium channels.</span></span></div>
<span class="Apple-style-span" style="font-family: inherit;"><span class="reflink plainlinks nourlexpansion"></span></span><br />
<a href="http://2.bp.blogspot.com/-vYraVDaUB-4/Tf9tMtJCcFI/AAAAAAAAACk/KnK4Dq4EMT0/s1600/800px-Retigabine.svg.png"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5620330925025030226" src="http://2.bp.blogspot.com/-vYraVDaUB-4/Tf9tMtJCcFI/AAAAAAAAACk/KnK4Dq4EMT0/s320/800px-Retigabine.svg.png" style="cursor: pointer; display: block; height: 134px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; text-align: left; width: 320px;" /></a><span class="Apple-style-span" style="font-family: inherit;"></span><br />
<span class="Apple-style-span" style="font-family: inherit;"></span><br />
<div style="text-align: left;">
<span class="Apple-style-span" style="font-family: inherit;"><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Ezogabine (canonical smiles</span></span><span class="Apple-style-span" style="font-family: inherit;">    CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N      </span><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">, standard InChI InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)) has 6 rotatable bonds, a molecular weight of 303.3 Da, 3 hydrogen bond donors, 2 hydrogen bond acceptors, and is thus fully Rule-of-Five compliant.</span></span></span></div>
</div>
<div style="text-align: justify;">
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><br />
</span> </span></div>
</div>
<div style="text-align: justify;">
<div style="text-align: left;">
<span class="Apple-style-span" style="font-family: inherit;"><span class="reflink plainlinks nourlexpansion"></span></span><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Ezogabin </span><a href="http://www.if-pan.krakow.pl/pjp/pdf/2009/2_197.pdf"><span class="Apple-style-span" style="font-family: inherit;">has</span></a><span class="Apple-style-span" style="font-family: inherit;"> moderately high bioavailability (50-60%), a high volume of distribution (6.2 L/kg) and a terminal half-life of 8 to 11 hours. Potiga tablets are administered three times daily. Ezogabine has  a number of potentially&nbsp;</span><a href="http://www.blogger.com/www.fda.gov/downloads/Drugs/DrugSafety/UCM259619.pdf"><span class="Apple-style-span" style="font-family: inherit;">severe adverse effects</span></a><span class="Apple-style-span" style="font-family: inherit;">, such as </span><a href="http://en.wikipedia.org/wiki/Urinary_retention"><span class="Apple-style-span" style="font-family: inherit;">urinary retention</span></a><span class="Apple-style-span" style="font-family: inherit;">, and psychiatric symptoms such as new or intensification of depression, anxiety, psychosis, and in rare cases suicidal thoughts.</span></span><span class="Apple-style-span" style="font-family: inherit;">&nbsp;</span></div>
</div>
<div style="text-align: justify;">
<div style="text-align: left;">
<span class="Apple-style-span" style="font-family: inherit;"><br />
</span></div>
</div>
<div style="text-align: justify;">
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Potiga has been developed by </span><a href="http://www.valeant.com/"><span class="Apple-style-span" style="font-family: inherit;">Valeant</span></a><span class="Apple-style-span" style="font-family: inherit;"> and will be marketed by </span><a href="http://www.gsk.com/"><span class="Apple-style-span" style="font-family: inherit;">GSK</span></a><span class="Apple-style-span" style="font-family: inherit;">.</span></span></div>
</div>
<div style="font-family: times new roman; text-align: justify;">
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><br />
</span> </span></div>
</div>
<div style="font-family: times new roman; text-align: justify;">
<div style="text-align: left;">
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Full prescribing information </span><a href="http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-468753.htm"><span class="Apple-style-span" style="font-family: inherit;">will become available</span></a><span class="Apple-style-span" style="font-family: inherit;"> at launch of the drug.</span></span> </div>
</div>